From Financial Modeling Prep: 2025-05-19 18:02:00

Compugen Ltd. (NASDAQ:CGEN) specializes in drug discovery in the Medical – Biomedical and Genetics industry, focusing on immuno-oncology. However, their recent earnings report showed missed estimates, with an EPS of -$0.08 (vs. estimated -$0.06) and revenue of $2.28 million (vs. estimated $3.70 million).

The negative surprise in earnings was 33.33%, reflecting a challenging quarter for Compugen. The company’s revenue shortfall of 38.35% compared to estimates further highlights the financial difficulties faced in the recent period.

Despite the financial challenges, Compugen maintains a low debt-to-equity ratio of 0.053 and a strong current ratio of approximately 5.26, showcasing financial stability amidst the earnings and revenue miss.

Investors may find some confidence in Compugen’s price-to-sales ratio of 4.73, indicating potential in sales growth. The company’s enterprise value to sales ratio of 4.18 provides insight into its valuation relative to sales, offering a perspective on investor sentiment towards Compugen.



Read more at Financial Modeling Prep:: Compugen Ltd. (NASDAQ:CGEN) Misses Earnings and Re…